Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research（2023）
摘要
The combination of dasatinib 60 mg/m2/dose daily and ganitumab 18 mg/kg every two weeks was safe and tolerable. This combination had a disease control rate of 22% at five months.
更多查看译文
关键词
rhabdomyosarcoma,src family kinase,ganitumab,dasatinib,insulin-like
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要